Last reviewed 2026-06-10 · How we verify

Type 2 diabetes mellitus in obese — Treatment Landscape & Competitive Intelligence

Type 2 diabetes mellitus in obese (disease) competitive landscape: 0 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Type 2 diabetes mellitus in obese, deduplicated by molecule. See the full disease page for line-of-therapy detail.

No marketed treatments tracked for this disease yet.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Type 2 diabetes mellitus in obese:

• Type 2 diabetes mellitus in obese treatment updates — RSS
• Type 2 diabetes mellitus in obese treatment updates — Atom
• Type 2 diabetes mellitus in obese treatment updates — JSON

Cite this brief

Drug Landscape (2026). Type 2 diabetes mellitus in obese — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/type-2-diabetes-mellitus-in-obese. Accessed 2026-06-10.

Related

• Type 2 diabetes mellitus in obese full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing